265 related articles for article (PubMed ID: 20534267)
1. Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment--a single-center experience.
Perrella A; Esposito C; Ioia G; Campanella L; Taglialatela D; Cuomo O
Transplant Proc; 2010 May; 42(4):1226-8. PubMed ID: 20534267
[TBL] [Abstract][Full Text] [Related]
2. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
Fricke L; Steinhoff J; Hartwig-Weber I; Bein G
Dtsch Med Wochenschr; 1997 May; 122(18):565-71. PubMed ID: 9190308
[TBL] [Abstract][Full Text] [Related]
3. The effect of donor-recipient cytomegalovirus serology on adult liver transplantation: a single center experience.
Tryphonopoulos P; Weppler D; Morris MI; Russo C; Nishida S; Levi DM; Moon J; Tekin A; Selvaggi G; Island E; Arosemena L; Ruiz P; Tzakis AG
Transplantation; 2011 Nov; 92(9):1051-7. PubMed ID: 21876474
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors for cytomegalovirus infection after orthotopic liver transplantation using an ultrasensitive polymerase chain reaction assay.
Basse G; Esposito L; Mengelle C; Kamar N; Ribes D; Lavayssière L; Pillet A; Suc B; Barange K; Rostaing L
Transplant Proc; 2006 Sep; 38(7):2339-41. PubMed ID: 16980084
[TBL] [Abstract][Full Text] [Related]
6. CMV hepatitis after liver transplantation: incidence, clinical course, and long-term follow-up.
Seehofer D; Rayes N; Tullius SG; Schmidt CA; Neumann UP; Radke C; Settmacher U; Müller AR; Steinmüller T; Neuhaus P
Liver Transpl; 2002 Dec; 8(12):1138-46. PubMed ID: 12474153
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
[TBL] [Abstract][Full Text] [Related]
8. Gancyclovir prophylaxis in high risk patients.
Campino A
Transplant Proc; 2005 Dec; 37(10):4311-2. PubMed ID: 16387106
[TBL] [Abstract][Full Text] [Related]
9. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus infection in kidney transplant recipients: Evolution of approach through three eras.
Boucher A; Lord H; Collette S; Morin M; Dandavino R
Transplant Proc; 2006 Dec; 38(10):3506-8. PubMed ID: 17175316
[TBL] [Abstract][Full Text] [Related]
12. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
13. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
[TBL] [Abstract][Full Text] [Related]
14. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
Peggs KS; Preiser W; Kottaridis PD; McKeag N; Brink NS; Tedder RS; Goldstone AH; Linch DC; Mackinnon S
Br J Haematol; 2000 Dec; 111(3):782-90. PubMed ID: 11122138
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
[TBL] [Abstract][Full Text] [Related]
16. Risk factors associated with cytomegalovirus infection in orthotopic liver transplant patients.
Hoppe L; Marroni CA; Bressane R; Lago L; Schiavo FL; Cigerza GC; Brandão AB; Zanotelli ML; Cantisani GP
Transplant Proc; 2006; 38(6):1922-3. PubMed ID: 16908324
[TBL] [Abstract][Full Text] [Related]
17. The value of pre-emptive therapy for cytomegalovirus after liver transplantation.
Müller V; Perrakis A; Meyer J; Förtsch T; Korn K; Croner RS; Yedibela S; Hohenberger W; Schellerer VS
Transplant Proc; 2012 Jun; 44(5):1357-61. PubMed ID: 22664015
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus infection and disease following renal transplantation: preliminary report of incidence and potential risk factors.
Taherimahmoudi M; Ahmadi H; Baradaran N; Montaser-Kouhsari L; Salem S; Mehrsai A; Kalantar E; Jahani Y; Pourmand G
Transplant Proc; 2009 Sep; 41(7):2841-4. PubMed ID: 19765452
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients.
Casillo R; Grimaldi M; Ragone E; Maiello C; Marra C; De Santo L; Amarelli C; Romano G; Della Corte A; Portella G; Tripodi MF; Fortunato R; Cotrufo M; Utili R
Transplant Proc; 2004 Apr; 36(3):651-3. PubMed ID: 15110622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
